Fig. 5.

AU-011 as a single agent and in combination with immune checkpoint inhibition in murine tumor models. A C57BL/6 mice were inoculated with 0.5 × 10⁶ MC38 cells in the right flank. At 7 days post inoculation, when tumors were established (125 mm³), the mice were injected with 100 µg of AU-011 intravenously into the tail vein. The tumors were then illuminated with NIR light (690 nm) at a DLI of 12 h with 400 mW/cm² for 75 J/cm². At days 8, 10, 13 and 16 post inoculation, immune checkpoint inhibitory antibodies CTLA-4 (200 µg per administration), PD-L1 (200 µg per administration), LAG-3 (200 µg per administration) or LAG-3 together with PD-L1 (150 µg of each antibody per administration) were injected intraperitoneally, after which the animals were monitored over time. B Animal weight of all groups. C Tumor volume and survival curves of the animals treated with CTLA-4, PD-L1, PDT with CTLA-4 and PDT with PD-L1. D Tumor volume and survival curves of the animals treated with LAG-3, LAG-3 + PD-L1, PDT with LAG-3 and PDT with LAG-3 + PD-L1. Statistical analysis was performed using the ANOVA at day 20 post inoculation for comparison of tumor volume and the Mantel-Cox test for a comparison of survival. (*p < 0.05; mean ± SEM; n = 7–12)